CiNTL Pharma Publications
Insights on clinical trial execution, risk management, and data-driven development

CiNTL Pharma B.V. The race to bring new medicines to patients is not just a scientific endeavor. It is increasingly a geopolitical one. The United States, China, and Europe each operate distinct drug development and regulatory ecosystems, and the differences between them are growing more consequential. For pharmaceutical companies navigating global development strategies, understanding where approvals happen fastest and why is no longer optional. It is a strategic necessity.

CiNTL Pharma B.V. The clinical trial industry is overdue for a reckoning. For years, pharmaceutical companies and CROs have relied on legacy eClinical platforms, bloated, siloed, and fundamentally fragmented systems that were built for a different era of drug development. As the demands of modern clinical trials grow more complex, these platforms are increasingly becoming a liability rather than an asset. Smarter CROs are taking note and building a competitive advantage by ad

CiNTL Pharma B.V. The pharmaceutical industry stands at an inflection point. Agentic AI is not a future possibility. It is here, operational, and already delivering measurable advantages to the sponsors and CROs that have embraced it. The question is no longer whether AI will transform clinical trial management. It already has. The only question is whether your organization will be among those leading the transformation, or among those scrambling to catch up. What Agentic AI